SciELO - Scientific Electronic Library Online

 
vol.40 número1Evolución de la cultura de seguridad del paciente en un hospital de media-larga estancia: indicadores de seguimientoRelación entre el índice de Onodera pre-operatorio y las complicaciones post-cirugía R0 en el cáncer de estómago índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Anales del Sistema Sanitario de Navarra

versión impresa ISSN 1137-6627

Resumen

JUANBELTZ, R. et al. Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. Anales Sis San Navarra [online]. 2017, vol.40, n.1, pp.57-66. ISSN 1137-6627.  https://dx.doi.org/10.23938/assn.0006.

Background.

Second-generation direct-acting antivirals (DAA) have shown high sustained virologic response (SVR) for the treatment of chronic hepatitis C in clinical trials. The objective of this study is to estimate DAA effectiveness in treatment of this disease.

Methods.

Hepatitis C virus (HCV) monoinfected patients and HCV-human immunodeficiency virus (HIV) coinfected patients who started interferon-free DAA based regimens during 2015 were included. The primary effectiveness outcome was SVR, defined as an undetectable viral load 12 weeks after the end of treatment.

Results.

A total of 293 patients were enrolled, and 52 (17.7%) were HIV coinfected. HCV 1b genotype was the most prevalent in monoinfected patients (41.5%) and 1a in HIV coinfected patients (40.4%). The proportion of cirrhosis was higher among HIV coinfected patients (69.2% vs 41.1%; p<0.0001), mostly Child-Pugh A. SVR was achieved by 96.9% of patients (284/293), in an intention-to-treat analysis (CI 95%: 94.9-98.9), in which just 4 people had virologic failure. Both naïve and pretreated patients had SVR higher than 95%, and in most of subgroups, according to the presence of cirrhosis, HIV coinfection and HVC genotype, effectiveness rates were near or above 90%.

Conclusions.

DAA are highly effective, with similar or higher rates of SVR than that found in clinical trials, and even among difficult to treat populations.

Palabras clave : Chronic hepatitis C; HIV; Antiviral agents; Treatment outcome; Clinical practice pattern.

        · resumen en Español     · texto en Español     · Español ( pdf )